Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).
Kim, D. W. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a753 (2012).
Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).
Scagliotti, G. et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14, 253–263 (2009).
Camidge, D. R. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774–780 (2011).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Davies, K. D. & Doebele, R. C. Molecular pathways: ROS1 fusion proteins in cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-12-2851.
Ou, S. H. I. et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a8032 (2013).
Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395–2401 (2013).
Camidge, D. R. & Doebele, R. C. Treating ALK-positive lung cancer--early successes and future challenges. Nat. Rev. Clin. Oncol. 9, 268–277 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received research grants from Eli Lilly & Co., ImClone Systems and Pfizer, and advisory board and consulting fees from Boehringer Ingelheim and Pfizer.
Rights and permissions
About this article
Cite this article
Doebele, R. Time to shift the burden of proof for oncogene-positive cancer?. Nat Rev Clin Oncol 10, 492–493 (2013). https://doi.org/10.1038/nrclinonc.2013.135
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.135